PCSK9 is a promising prognostic marker in patients with advanced NSCLC
- 33 Downloads
AB, FG, and FM equally contributed to the writing and revision of the manuscript draft and approved the final version.
This study was supported by a grant from the Italian Ministry of Health to the Italian Cardiovascular Network (#2754291) and a grant from the Fondazione CARIGE to Prof. Fabrizio Montecucco. The PD-1/PD-L1 analyses were supported by a grant from Compagnia San Paolo (SC: 2017-0529).
Compliance with ethical standards
Conflict of interest
Francesco Grossi has consulting/advisory relationship with and received honoraria from Bristol-Myers Squibb, Merck Sharp and Dohme, and Pierre Fabre and has consulting/advisory relationship with AstraZeneca and Roche. All other authors declare that there are no conflicts of interest.
The study was approved by the Institutional Review Board of IRCCS Ospedale Policlinico San Martino, Genoa, Italy (registry number: P.R. 191REG2015). The study was conducted in accordance with the Declaration of Helsinki and consistent with International Conference on Harmonization (ICH) Guidelines for Good Clinical Practice.
Prior to inclusion in the study, all patients gave written, informed consent to the use of their samples and data for research and scientific publications.